Работы, цитирующие эту работу

Работ: 2

Работа: May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?

1. Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»)

   E. I. Tarlovskaya, A. G. Arutyunov, А. О. Конради +97

   СтатьяLong-Term Effects of COVID-19Kardiologiia2021Цитирований: 0

   ABIABI:AkademIndex/openalex/2021.article.000346

2. Nanoparticle-Based PCSK9 Inhibition in Viral Infections: Evaluating Clinical Limitations and Advancing Therapeutic Strategies

   Moeen F. Dababneh, Bahjat Alhasso, Abdulkareem Shareef +10

   СтатьяLipoproteins and Cardiovascular HealthJournal of Pharmaceutical Innovation2026Цитирований: 0

   ABIABI:AkademIndex/openalex/2026.article.013240